Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects

BACKGROUND: Imeglimin is a first-in-class novel oral antidiabetic marketed in Japan as TWYMEEG(®) to treat type 2 diabetes mellitus. Its mode of action is distinct from all other anti-hyperglycemic classes. OBJECTIVE: To assess the pharmacokinetic and safety profile of imeglimin in Caucasian and Jap...

Descripción completa

Detalles Bibliográficos
Autores principales: Fouqueray, Pascale, Chevalier, Clémence, Bolze, Sébastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427879/
https://www.ncbi.nlm.nih.gov/pubmed/35867199
http://dx.doi.org/10.1007/s40261-022-01181-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427879/
https://www.ncbi.nlm.nih.gov/pubmed/35867199
http://dx.doi.org/10.1007/s40261-022-01181-3

Ejemplares similares